



The Global Language of Business

Panel I Donor organisations implementing GS1 Standards

Wednesday November 6, 2019
GS1 Healthcare Conference New Delhi, India



A photograph of two young girls in school uniforms laughing together in a rural field. The girl on the right is wearing a light blue school shirt and has her arms around the girl on the left, who is wearing a red and grey patterned shirt. They are both smiling broadly. The background shows a field of tall grass and some buildings in the distance under a clear sky.

**GS1 standards deployment is part of Global
Fund Supply Chain strategy**
Mouna Jarmouni

 **The Global Fund**



Mouna Jarmouni

Supply Chain Data &
Performance Lead

- 14 years of experience in Global Supply chain Management, purchasing, logistics, warehouse management and data & analytics management
- As an expert in Supply Chain Management, experienced in healthcare supply chain management, working for Novartis /GSK Consumer healthcare supporting Data Processes, Portfolio Optimization/Value engineering process improvement
- Now devoted to the Global Fund Mission focused on Supply Chain Performance, data & analytics, execution systems to increase data visibility and support Digital health related activities rapidly growing low and middle income countries



Mouna.jarmouni@TheGlobalFund.org



Twitter



LinkedIn



PREPARATORY MEETING – SIXTH REPLENISHMENT

New Delhi, India
2020-22



US\$14 Billion to Step Up the Fight Against the Epidemics



Results that matter

Smart, effective health investments through the Global Fund have saved 32 million lives, expanding opportunities and achieving greater social justice for families and communities worldwide.

Scientific advances, innovative ideas and private sector savvy are unlocking improvements in disease prevention, treatment and care. Millions of people are now on antiretroviral therapy and spared the death sentence that used to come with HIV. The number of people dying of malaria, most of them young children, has been cut in half. New diagnostics systems are speeding up the testing and treatment of people with TB.

But we can't stop now. Adolescent girls are contracting HIV at a terrible rate in southern Africa. Multidrug-resistant TB is growing into a potentially catastrophic threat to public health. Gains made against malaria could be lost if we don't expand prevention and treatment programs.

Millions more lives are still at risk. We must seize the momentum, be ambitious and move faster to end HIV, TB and malaria as epidemics.



A 21ST-CENTURY PARTNERSHIP

The Global Fund's partnership model is designed to promote innovative solutions. With a 21st-century approach that encourages agile responses and maximum participation, countries take the lead in determining where and how to best fight diseases. Collectively, we harness the best possible experience, insights and innovation in the public and private sectors, from faster delivery of essential medicines to more effective methods to reach the people most in need.

HOW IT WORKS

OVERSIGHT IN ACTION

Local Fund Agents in each country monitor implementation of grants. The Global Fund's Office of the Inspector General conducts audits and investigations.

LOCAL EXPERTS IMPLEMENT

Local experts and partners use grant money to deliver programs. Impact is continuously monitored and evaluated.

WE RAISE THE MONEY

The Global Fund raises and invests more than US\$4 billion a year to support programs run by local experts in more than 100 countries. The money comes 93% from donor governments and 7% from the private sector and foundations.

COUNTRIES MAKE INVESTMENT DECISIONS

A Country Coordinating Mechanism made up of representatives of people whose lives are affected by the three diseases, medical experts, government and civil society meets and develops a plan to fight the diseases in their community.

WE REVIEW AND APPROVE

An independent panel of experts reviews the plan to determine if it will achieve results. The panel may request changes to the plan. Once finalized, it goes to the Global Fund's Board for approval.

WHERE THE PROGRAMS ARE





It has helped **speed up patient reporting** by community health workers, **expedite payments** to health workers and **prevented stock-outs of medicines**


Why GS1 are important for The Global Fund?

Vision Statement

We purchase ~\$1.2B of “**efficient and safe**” products per year and our vision is to trace all products across the complete supply chain up to the final patient to avoid counterfeiting.

Goals & Objectives

- ✓ Enabling a **secure and efficient supply chain** from source through to medication dispensing points and operating rooms
- ✓ Enabling end-to-end data visibility with **automated transaction and data-sharing** that eliminate manual data entry, validation and correction, reducing errors and costs
- ✓ **Identifying and implementing supply chain efficiencies**, minimizing product waste, less time in recalls and more in patients, improving care)
- ✓ **Ensuring supply chain security** to help pharmacies, hospitals and physicians identify counterfeit drugs and reimbursement fraud
- ✓ Improving patient safety



Supply chain data standards will greatly improve healthcare safety and efficiency, but safety is our primary value. The needs of the patient come first

**ENDING AIDS,
TB AND MALARIA
AS EPIDEMICS**

Our Supply Chain Strategy



We agreed to link health outcomes to patient impact and functional KPIs, like those for supply chain

Health outcomes

Key health outcome indicators

- 90% of people know their status
- 90% of people on antiretroviral therapy
- 90% of people are virally suppressed

Disease summary data


- Number of people living with HIV/AIDS
- Reduction of AIDS-related deaths
- Reduction of new infections / cases

Patient impact


- Awareness & usage
- Accessibility
- Availability
- Affordability
- Assured quality

**Functional KPIs
Supply Chain**

- On shelf availability (OSA)
- Inventory turnover
- Product wastage
- SC cost per product / patient
- Compliance to GS1



On Shelf Availability: Access to Health Products are trending upwards, but improvements are still necessary to avoid treatment / diagnostics disruption



90% still means that 10 out of 100 people seeking health products leave clinics empty handed.

In rural areas where people only go to town once a month, the disruption of treatment is high.


Risking impact in fighting HIV, Malaria and TB

NEXT STEPS: Collaborate

We will build on and further shape our current supply chain implementation plan up to November 2019



Test in 5 African countries




Global standards could help save thousands of lives and billions of dollars each

Global standards could be a critical enabler to improving the safety and quality of patient care in a cost-effective way. These standards have greater potential to improve care and save resources if they are truly global and adopted by all stakeholders, **including manufacturers, distributors, wholesalers, pharmacies, and providers and also governments, Regulators and Development organizations.**

Universally accepted methods for identifying products and locations and exchanging data could enable organizations to share vital information along the entire value chain, eliminating today's broad array of custom data configurations, while improving:

- compatibility and interoperability,
- reducing redundancy,
- preventing medication errors,
- enhancing visibility,
- and enabling seamless, automated information exchange among supply chain partners.



“When I first mooted the idea of the Global Fund, people said I was dreaming... I love dreams. It always starts with a dream.”

Kofi Annan, Secretary General of the United Nations (April 2001)



USAID
FROM THE AMERICAN PEOPLE

USAID Implementation of GSI Standards

GSI Global Healthcare Conference

New Delhi - November 6, 2019

Ramy Guirguis, Ph.D.

Senior Information Technology Advisor

USAID | Bureau for Global Health

rquiguis@usaid.gov





Dr. Ramy Guirguis

Senior Information
Technology Advisor

USAID | Bureau for Global
Health

Dr. Guirguis holds a Ph.D, M.Sc., and B.Sc. in Computer and System Engineering. Dr. Guirguis is currently a Senior Information Technology Advisor with USAID's Global Health Supply Chain, where he advises countries with respect to the automation of their national-level public health supply chain system. Dr. Guirguis also provides an oversight to USAID's global MIS systems for supply chain. He has over 30 years of professional experience in information and communications Technology and contributed to the transformation and modernization of several large enterprises and government agencies spanning many diverse sectors including the: telecommunications, financial, health, defense and development sectors for both public and private sectors in the USA and internationally. Dr. Guirguis represented the DoD at several standards bodies, in the U.S. and overseas. He was a member of the U.S. expert delegation at several ISO/IEC JTC1/SC37 standards meetings. Dr. Guirguis is an Adjunct Professor at Georgetown, authored & co-authored four patents, presented several papers at international conferences. He is an IEEE Senior Member, Senior Fellow at GMU International Cyber Center, PMI member and Certified Project Management Professional (PMP).



Rguirguis@usaid.gov



<https://twitter.com/ramyguirguis>




<https://www.linkedin.com/in/ramyguirguis/>

Presentation Outline


- USAID Global Health Supply Chain (<https://www.youtube.com/watch?v=mpeCXtCYi-E>)
- Phase 1 Supplier Compliance (Rachel)
- Phase 2 Building GSI Foundation for Public Health Information Systems in LMIC
 - Current Challenges with Product Master
 - National Product Catalog Initiative
- Global Product Catalog



Example of Pharmaceutical Supply Systems - Malawi




Example of Current Product Physical and Data Flow



- Physical commodity moves from one supply chain partner to another,
 - Whereas product data & information associated with this commodity does not
- Each SC partner maintains its own set of information affecting data consistency & quality,
 - Thereby limiting end-to-end data visibility, traceability & the ability to plan effectively

Compliance requirements in the USAID/GHSC-PSM supply chain



Current Challenges

1) Problem Statement:

Inability to scan GSI barcodes on commodity package labels, to improve efficiency, data quality and to facilitate track and trace


2) Problem Statement:

Inability to integrate between multiple application/systems that have different product coding methods


3) Problem Statement:

High degree of error and effort to maintain product definitions that are aligned between multiple systems (often maintained by different organizations)

Product Master Data - Major Challenges



Impacts...



Operational Efficiency



Traceability



Planning



Product Verification




Interoperability



End-to-End Visibility

Importance of Product Master Data

Public Health Information Systems




Product

- **Basic Information**
 - ID, Description, Unit of Measure, Product Characteristics/Specifications, Attributes
- **Classification Details**
- **GSI Attributes (GTIN)**
- **Pricing Information**
- **Manufacturer**
 - Manufacturer Name & Address (GLN), Country of Origin
- **Inventory Information**
 - Packaging, Storage, Shelf life, Tag / Serial # Controlled
- **Compliance**
 - Registration Details, Labeling




Patients & End Consumers

Processes / Transactions




Addressing Challenges through Process & People



National Product Catalog


NPC Product Code	Description
02345898873	Paracetamol tab 500mg

GTIN:	02345898873
PRIMS Registration No.:	20/1939/DGCS/PH/2014
WMS/eLMIS Product Code:	N02BE01020001E
Private Sector Product Code:	10AB00123
HMIS Product Name:	Paracetamol tab 500mg



Addressing Challenges through Technology


National Product Catalog Architecture



Conclusion

- Standardized (GSI) product information is the foundation for data visibility and traceability:
 - GTIN
 - Attributes
 - Classification
- There is an urgent need for Donors and Manufactures to collaborate to make product information available for countries.

Thank You



USAID
FROM THE AMERICAN PEOPLE



Implementation of Global Standards within the USAID GHSC-PSM Supply Chain

Rachel Smith, Global Standards Technical Specialist

Photo: GHSC-PSM



Rachel Smith

Global Standards Technical
Specialist, USAID GHSC-
PSM

About Me

Rachel Smith is a Global Standards Technical Specialist at the USAID Global Health Supply Chain Program – Procurement and Supply Management (GHSC-PSM), where she specializes in supplier engagement for the implementation of global standards within GHSC-PSM’s global supply chain. In addition to that, she has supported initiatives related to supply chain data visibility, traceability, master data management, and analytics for global health. She holds a Master’s degree in Quantitative Methods in the Social Sciences from Columbia University.



rsmith@ghsc-psm.org



[linkedin.com/in/rachel-l-smith-59349960/](https://www.linkedin.com/in/rachel-l-smith-59349960/)



What is GHSC trying to achieve?

Vision

To enable identification of every item procured at every point in the supply chain, through administration to the patient

Goal


To enable a secure and efficient supply chain from source through to service delivery

Objectives

- To enable end-to-end data visibility
- To identify and implement supply chain efficiencies
- To ensure supply chain security
- To increase patient safety




Cross-Cutting Approach




Strategic Engagement

Supporting USAID in engaging the global health community to build consensus and align requirements between donors and their procurement agents



Health Systems Strengthening

Developing a set of frameworks and tools to support country governments and their implementing partners in developing strategies for global standards and traceability implementations



Global Supply Chain

Implementing standard identification, labeling, and master data synchronization for all pharmaceuticals, medical devices, sterile kits, and reagents


Joint donor guideline

- Guidance on identification, data capture, and data sharing aligned with global standards
- Document is endorsed by Global Drug Facility (Stop TB), Global Fund, UNFPA, UNDP, and USAID
- Agency-specific timelines for implementation are included in Annex C
- Implemented by donor procurement agents through their respective supplier contracts



Available: <http://ghsupplychain.org/global-standards-technical-implementation-guideline-global-health-commodities-v21>

GHSC-PSM Contract Requirements





Progress by the numbers

2546

items with **GTINs** provided

1855

items with Phase I **tertiary packaging** verified

183

items **ahead of schedule** on packaging requirements

59

suppliers have submitted evidence of compliance



Phase I AIDC Requirements

SUCCESSSES

High-volume, homogenous product groups like:

- HIV/AIDS Treatment
- Malaria Treatment
- Malaria Diagnostics
- Contraceptives

CHALLENGES

Categories and suppliers with high levels of variation like:

- Wholesalers
- New suppliers
- Low-volume categories
- Low-volume suppliers

Looking ahead to Phase 2



Managing supplier compliance




VS.



Factoring compliance into performance

Global standards compliance is now:

- A dedicated component of every quarterly supplier performance review
- Factored into past performance when evaluating new contract awards
- Factored into strategic sourcing and order allocation decisions



Recognizing top performers

We publish names of suppliers with >95% compliance against each deadline, including future deadlines, on our website and seek to promote more broadly in the future as a means of recognition

Suppliers with greater than 95% GS1 compliance

Phase 1

- Abbott Molecular Inc
- AbbVie Inc.
- Access Bio Inc.
- Ajanta Pharma Ltd.
- Aurobindo Pharma Limited
- Bayer AG
- Cipla Limited
- Emcure Pharmaceuticals Limited
- Fosun Pharmaceutical Distribution Jiangsu Co., Ltd
- Guilin Pharmaceutical Co., Limited
- Hetero Labs Limited
- Laurus Labs Limited
- Macleods Pharmaceuticals Limited
- Merck, Sharp + Dohme B.V.
- Mylan Laboratories Limited
- Novartis Pharma Services AG
- Pfizer Overseas LLC
- Pregna International Limited.
- Premier Medical
- Roche Diagnostics
- Sanofi Winthrop Industries
- Standard Diagnostics, Inc.
- Strides Shasun Limited
- Sysmex Europe GmbH
- Veru Inc.

Phase 2

- Merck, Sharp + Dohme B.V.
- Novartis Pharma Services AG
- Pregna International Limited

Phase 3

- AbbVie Inc.
- Access Bio Inc.
- Ajanta Pharma Ltd.
- Aurobindo Pharma Limited
- Cipla Limited
- Emcure Pharmaceuticals Limited
- Fosun Pharmaceutical Distribution Jiangsu Co., Ltd
- Guilin Pharmaceutical Co., Ltd.
- Ipca Laboratories Ltd.
- Macleods Pharmaceuticals Limited
- Merck, Sharp + Dohme B.V.
- Mylan Laboratories Limited
- Pfizer Overseas LLC
- Pregna International Ltd.
- Premier Medical
- Roche Diagnostics (Pty) Ltd.
- Strides Shasun Ltd.
- Suretex Ltd.
- Veru Inc.

Phase 4

- Ajanta Pharma Ltd.
- Cipla Limited
- Emcure Pharmaceuticals Limited
- Fosun Pharmaceutical Distribution Jiangsu Co., Ltd
- Guilin Pharmaceutical Co., Limited
- Ipca Laboratories Ltd.
- Macleods Pharmaceuticals Limited
- Merck, Sharp + Dohme B.V.
- Pregna International Ltd.
- Premier Medical
- Roche Diagnostics (Pty) Ltd
- Strides Shasun Limited
- Suretex Limited
- Veru Inc.

Available: <http://ghsupplychain.org/GSI/SupplierScorecard>



Lessons learned

- Strategy requires multiple components:
 - ✓ Phased implementation is necessary for feasibility
 - ✓ Adequate lead time to ensure that suppliers can implement
 - ✓ Strong feedback loop to support and achieve high-quality outputs
- Dedicated resources are critical for informed feedback and proactive engagement
- Suppliers and procurers need to be partners to make the initiative a success

THANK YOU FOR YOUR COLLABORATION

The USAID Global Health Supply Chain-Procurement and Supply Management project provides commodity procurement and logistics services, strengthens supply chain systems, and promotes commodity security.

We support USAID programs and Presidential Initiatives in Africa, Asia, Latin America, and the Caribbean, focusing on HIV/AIDS, malaria, and population and reproductive health commodities.

OUR WEBSITE: <http://ghsupplychain.org/globalstandards>



Sourav Mitra

Vice President Global
Packaging Strategy
Mylan

A creative packaging professional and leader with over 22+ years of experience in Pharmaceutical and FMCG Industry.

Sourav has been front runner spearheading and executing key Global projects on Pharmaceutical packaging.



Pascal Aulagnet

Senior Manager
Pfizer Digital,
Pfizer Inc

My responsibilities include managing relationship with internal and external stakeholders related to serialization and track and trace. I represent Pfizer externally on various industry groups related to the implementation of existing regulations or planned regulations at regional and country level and liaise internally with the Pfizer Digital organization and market colleagues to implement the requirements.

I am the EFPIA representative in the European Medicines Verification Organization Technical Advisory Group and member of the French trade association steering committee for the FMD implementation where I work in different workstreams with the other stakeholders.

Since 2017, I represent Pfizer in the GS1 Healthcare Leadership Team.

I have 20 years of experience in the industry.




pascal.aulagnet@Pfizer.com





[Pascal Aulagnet](#)



[Pascal Aulagnet](#)



The benefits of improving visibility and security in the vaccines supply chain



36th Global GS1 Healthcare Conference – India

Pascal Aulagnet, Senior Manager Pfizer Digital, Pfizer Inc

6th November 2019 – New Delhi

Disclaimer

This presentation outlines a general technology direction. Pfizer Inc. has no obligation to pursue any approaches outlined in this presentation or to develop or use any functionality mentioned in this presentation. The technology strategy and possible future developments are subject to change and may be changed at any time for any reason without notice.

The views and opinions expressed in this presentation and any related discussion(s) are solely those of the individual presenter(s) and may not express the views of and opinions of Pfizer Inc.



Agenda



- Pfizer and its commitment to global health
- Background and History of Vaccine Visibility System Pilots
 - First Pilot in Nicaragua
 - Gambia implementation outcomes
- What's next

Breakthroughs that
change patients' lives

Pfizer's Commitment to Global Health

Our Approach: Leveraging the Full Extent of Our Resources and Partnerships

Through our partnerships and investments, we work to strengthen healthcare systems and increase access to quality healthcare for the most vulnerable people around the world



We work to strengthen service delivery systems through the expertise of our colleagues, invest in strategic partnerships to provide solutions to critical challenges, and increase access to medicines and vaccines through creative commercial partnerships

Pfizer's Commitment to Vaccine Access

For more than 10 years, Pfizer has been partnering with NGOs to build immunization programs and supply our pneumococcal vaccine to 50 developing countries across Africa, Asia, Latin America, the Middle East, and parts of Europe.

To date, we have shipped over 450 million doses to the world's poorest countries, and are committed to delivering 930 million doses by 2027.



Improving Visibility and Security in Pharmaceutical Supply Chains

- ❖ **Stock visibility and security are critical issues in many industries.** In healthcare, the supply chain from manufacturer to the patient is long and fragmented, especially in developing countries¹
- ❖ In 2011, the **World Health Organization's Vaccine Presentation and Packaging Advisory Group (VPPAG)** created a barcode subgroup to enable improved stock tracking in developing countries
- ❖ The group is facilitated by **GS1**, a neutral, non-profit organization that develops and maintains standards for supply and demand chains
- ❖ The inclusion of GS1 barcoding standards became a priority for manufacturers

Pfizer's partnerships with NGOs demonstrates its commitment to providing vaccines at affordable prices and improving access in the developing world.

Piloting a system to include scanning GS1 barcoding technologies differentiates Pfizer as an innovator in this space.

1) Accenture Supply Chain Security Strategy POV

Information coded into the GS1 barcode on PCV-13 packaging:

Capacity: 3116 Numeric or 2335 Alphanumeric characters

Omnidirectional: It can be scanned in any orientation, for speed of use.

PCV-13 Barcode Content:


- Global Trade Identification Number (GTIN)
- Manufacturing Lot Number
- Vaccine Vial Expiry date

Pfizer's case study of VVS

- Pfizer has participated in case studies on the implementation of a Vaccines Visibility System
- First Pilot implementation in Nicaragua followed by an enhancement of the system to add more functionalities and extension in the utilization
- A second pilot in Gambia


Vaccines Visibility System (VVS) – First Pilot in Nicaragua

- The pilot developed a tool (VVS) that integrated barcode scanning with the processes and reporting requirements of the Nicaragua Ministry of Health (MoH).
- VVS was created by building on PHP (PATH Proof of Principle solution), a module of the OpenLMIS Logistics Management Information System in use in Tanzania. The functionality of PHP was enhanced by gathering and implementing requirements from the existing inventory management tool (VSSM) in use at the Nicaragua MoH.



Utilization of VVS within Supply Chain

VVS is utilized at several points throughout the supply chain, supporting end-to-end inventory management from the point of forecasting to real-time inventory reporting at health facilities.



LEGEND: **VVS** Stage in which VVS is utilized

Overview of PCV-13 Packaging

Pfizer has committed to including GS1 2D DataMatrix Barcodes on their Prevenar-13 (PCV-13) vaccine packaging at the tertiary, secondary, and primary levels of packaging.

Pfizer PCV-13 Label



GTIN: 65415062115017

Lot Number: L95321

Expiration Date: Oct 31 2017

How does VVS process the barcode information?

- ❖ Each unique GTIN corresponds to the type of packaging the vaccines are presented in (tertiary, secondary, or primary level packaging)
- ❖ Within the configuration of VVS Basic Data, each GTIN is assigned to a product, manufacturer, the number of vials per package, the number of doses per vial, and the physical volume of each dose
- ❖ Using the configured information, VVS is able to populate stock keeping data fields automatically when a box is scanned

Packaging Types

Tertiary Level

1800 vials per cardboard box



Secondary Level

50 vials per box



Primary level

Individual vials



Phase I : Benefits Realized using VVS

Benefits were observed in all the expected categories. The most significant advantage of VVS over the existing tools was its ability to reliably integrate data between all sites, at different levels of the supply chain.



Accuracy



Efficiency

Key Finding:

VVS *integrates* data that is entered at different sites and levels of the supply chain hierarchy with 4 distinct benefits

Key Next Steps:

- 1) Further improve integration benefit by expanding scanning footprint
- 2) Investigate feasibility of serialization



Visibility



Data Security

Phase II: Expanded Scanning Footprint for Gambia

To improve the capabilities of the VVS system, scanning was enabled within the Dispatches module and Arrivals modules to reap the most benefit in efficiency and accuracy of data entry.

Supply Chain Level	Packaging Type Received per Level	Activities Now Enabled by Scanning in VVS 2.0		
		Opening Stock	Arrival	Dispatch
National Store	Tertiary			
Districts	Secondary		 	
Regional	Secondary, Primary		 	
Health Centers	Primary	-	-	-

LEGEND



Established ability to scan within specified module



Integration between levels via Transaction Number




Newly enabled scanning functionality at specified module



*VVS not currently implemented at final level of supply chain and therefore does not have scanning functionality enabled

The Gambia Pilot: Status update

Pfizer and PATH deployed a Vaccine Visibility System (VVS) that utilizes 2D barcodes to improve the logistics management of vaccines in The Gambia



The Gambia Pilot: Preliminary Findings – Benefits of VVS

Overview of benefits high

Respondents:*

Benefit Category	Benefits	National (Blue)	Regional (Cyan)	District (Green)	Pending (Grey)
Visibility	<ul style="list-style-type: none"> Improved the overall visibility and management of the vaccines supply chain VVS alerts the user if the vaccine stock is below the minimum required amount 	3	1	1	3
Accuracy	<ul style="list-style-type: none"> Detected errors when inputting the information about the vaccine based on already saved information, minimising errors Improved the method of forecasting vaccines needs and future demand 	3	1	1	3
Efficiency	<ul style="list-style-type: none"> Enabled efficient stocks management – diversion of stocks to facilities in need Improved the process of ordering and dispatching vaccines Reduced the time in processing vaccines upon receipt 	3	1	1	3
Quality	<ul style="list-style-type: none"> Decreased the chances of stockouts or vaccine expiration Enabled optimal amount of vaccine storage allowing for more space in fridges 	0	1	1	3

“Before you had to force yourself to be on top of monitoring the stock. But with VVS, it warns you that an antigen is about to expire” – Regional Manager

“When running [vaccination] clinics – you always had to keep at the back of your mind which vaccines were in the fridge, and ... to update the system. Now, thanks to VVS I can focus on the clinics” – District User



*Note: Blue – national, cyan – regional, green – district, grey – pending interviews.

What's next?

Continue Collaboration

It's time to partner together – both governments and pharmaceutical companies – to operationalize and improve technology for the most impact.

What We Need:

- Government participation
- Pharma EPI programs alignment
- Alliance partners engagement
- Get the message out!
- Make this a priority



Barcode technology may increase access to potentially life-saving vaccines.

thank you!

Contact Information

Pascal Aulagnet

Senior Manager Pfizer Digital Market Customer Engagement, Pfizer Inc

Pfizer

Z.I de Pocé sur Cisse

Amboise , 37400 - France


-  • +33 1-580-738-18
-  • +33 6-843-223-51
-  • pascal.aulagnet@Pfizer.com



Follow us on Twitter and tweet about the conference!



@GS1Healthcare
#GS1HCDelhi



Be sure to complete each feedback form!



IN THE APP

For every feedback form completed, we will donate 5USD to the chosen conference charity **“HelpAge India”**

Be sure to complete each feedback form!



For every feedback form completed in the App, we will donate 5USD to the chosen conference charity **“HelpAge India”**



The Global Language of Business

COFFEE BREAK



Afternoon at a glance



Wednesday, 6 November

Networking lunch & visit of marketplace

Two parallel streams

Stream I – Stream I – Donor organisations implementing GS1 standards

Stream II – Public policy: Pharmaceuticals

Coffee Break

Two parallel streams

Stream I – Three Discussion Labs on specific areas of interest

Stream II – Traceability – Challenges and Learnings

**Think Tank
(by invitation only)**



Visit the Marketplace during lunch time



Meet the exhibitors in the **Allure Area**
Every day during breaks and luncheons



Thank you

